1831152-32-9 Usage
Chemical class
Boron-containing heterocycle
Structure
1H-pyrrole ring
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl group attached to the pyrrole ring
Composition
Carbon (C)
Hydrogen (H)
Nitrogen (N)
Oxygen (O)
Boron (B)
Potential applications
Organic synthesis
Pharmaceutical development
Agrochemical development
Unique features
Boron-containing moiety
Interesting target for chemical research and development
Possible properties or activities
Yet to be discovered
Future applications
Various industries, depending on the discovered properties or activities
This compound is a boron-containing heterocycle with a 1H-pyrrole ring and a 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl group. It is composed of carbon, hydrogen, nitrogen, oxygen, and boron. It has potential applications in organic synthesis, pharmaceuticals, and agrochemicals. Its unique structure and boron-containing moiety make it an interesting target for further research and development. The compound may have important properties or activities that are yet to be discovered, and it could have future applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1831152-32-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,3,1,1,5 and 2 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1831152-32:
(9*1)+(8*8)+(7*3)+(6*1)+(5*1)+(4*5)+(3*2)+(2*3)+(1*2)=139
139 % 10 = 9
So 1831152-32-9 is a valid CAS Registry Number.
1831152-32-9Relevant articles and documents
Identification of Noncompetitive Inhibitors of Cytosolic 5′-Nucleotidase II Using a Fragment-Based Approach
Marton, Zsuzsanna,Guillon, Rémi,Krimm, Isabelle,Preeti,Rahimova, Rahila,Egron, David,Jordheim, Lars P.,Aghajari, Nushin,Dumontet, Charles,Périgaud, Christian,Lionne, Corinne,Peyrottes, Suzanne,Chaloin, Laurent
, p. 9680 - 9696 (2015)
We used a combined approach based on fragment-based drug design (FBDD) and in silico methods to design potential inhibitors of the cytosolic 5′-nucleotidase II (cN-II), which has been recognized as an important therapeutic target in hematological cancers. Two subgroups of small compounds (including adenine and biaryl moieties) were identified as cN-II binders and a fragment growing strategy guided by molecular docking was considered. Five compounds induced a strong inhibition of the 5′-nucleotidase activity in vitro, and the most potent ones were characterized as noncompetitive inhibitors. Biological evaluation in cancer cell lines showed synergic effect with selected anticancer drugs. Structural studies using X-ray crystallography lead to the identification of new binding sites for two derivatives and of a new crystal form showing important domain swapping. Altogether, the strategy developed herein allowed identifying new original noncompetitive inhibitors against cN-II that act in a synergistic manner with well-known antitumoral agents.
